Raghad is a PhD student in the BIH Charité PhD Program, jointly supervised by Dr. René Hägerling and Dr. Annabell Krienelke-Szymansky. She joined CanEvo in July 2025, where she focuses on cancer evolution and the emergence of drug resistance in neuroblastoma using 3D organoid models. In addition to investigating resistance mechanisms, her project involves optimizing protocols for the long-term maintenance of primary patient-derived neuroblastoma organoids.

She completed her Master’s degree in Molecular and Translational Neuroscience at Ulm University, Medical Faculty, in 2024. Her thesis work, conducted at the University Hospital Ulm, focused on pediatric oncology and explored the synergistic anti-tumor effects of combining 5-ALA-based photodynamic therapy with Bcl-xL inhibition in medulloblastoma. This experience strengthened her interest in cancer biology, particularly in therapy resistance and tumor adaptation.

After graduation, Raghad completed an internship at Roche, where she was involved in the organization and preparation of a clinical trial. Motivated by her growing passion for oncology, she joined the CanEvo team to further deepen her experience in cancer research and contribute to advancing personalized therapeutic strategies.